1. refusal to sign informed consent form 2. negative test for covid-19 by rt-pcr at screening 3. severe disease symptomatically including pneumonia, respiratory distress, tachypnea, shortness of breath, temperature \> 38 degrees; pleuritic pain, or frequent cough. 4. known drug allergy to any of the investigational medications 5. currently taking medication with known drug interactions with investigational medications (listed in appendix) 6. prescription or other antiviral medications 7. any comorbidities which constitute health risk for the subject 8. pregnant or lactating females; 9. weight \< 110lb; 10. porphyria 11. established retinal disease 12. inability to attend daily for 10 days 13. any contraindications for treatment with hydroxychloroquine 1. hypoglycemia 2. known g6pd deficiency 3. porphyria 4. anemia 5. neutropenia 6. alcoholism 7. myasthenia gravis 8. skeletal muscle disorders 9. maculopathy 10. changes in visual field 11. liver disease 12. psoriasis 13. history of qt \>500msec 14. history of torsades de pointes 14. anemia from pyruvate kinase and g6pd deficiencies 15. abnormal ekg with qt prolongation acquired or from birth 16. history of jaundice or high fevers prior to developing covid-19 17. treatment with any of the medications listed in appendix ii 18. treatment with any anti-epileptic medication 19. treatment with any other drug not listed that affects the qt interval

1. refusal to sign informed consent form 2. negative test for covid-19 by rt-pcr at screening 3. severe disease symptomatically including pneumonia, respiratory distress, tachypnea, shortness of breath, temperature \> 38 degrees; pleuritic pain, or frequent cough. 4. known drug allergy to any of the investigational medications 5. currently taking medication with known drug interactions with investigational medications (listed in appendix) 6. prescription or other antiviral medications 7. any comorbidities which constitute health risk for the subject 8. pregnant or lactating females; 9. weight \< 110lb; 10. porphyria 11. established retinal disease 12. inability to attend daily for 10 days 13. any contraindications for treatment with hydroxychloroquine 1. hypoglycemia 2. known g6pd deficiency 3. porphyria 4. anemia 5. neutropenia 6. alcoholism 7. myasthenia gravis 8. skeletal muscle disorders 9. maculopathy 10. changes in visual field 11. liver disease 12. psoriasis 13. history of qt \>500msec 14. history of torsades de pointes 14. anemia from pyruvate kinase and g6pd deficiencies 15. abnormal ekg with qt prolongation acquired or from birth 16. history of jaundice or high fevers prior to developing covid-19 17. treatment with any of the medications listed in appendix ii 18. treatment with any anti-epileptic medication 19. treatment with any other drug not listed that affects the qt interval

refusal to sign informed consent form negative test for covid-19 by rt-pcr at screening severe disease symptomatically including pneumonia, respiratory distress, tachypnea, shortness of breath, temperature > 38 degrees; pleuritic pain, or frequent cough. known drug allergy to any of the investigational medications currently taking medication with known drug interactions with investigational medications (listed in appendix) prescription or other antiviral medications any comorbidities which constitute health risk for the subject pregnant or lactating females; weight < 110lb; porphyria established retinal disease inability to attend daily for 10 days any contraindications for treatment with hydroxychloroquine hypoglycemia known g6pd deficiency porphyria anemia neutropenia alcoholism myasthenia gravis skeletal muscle disorders maculopathy changes in visual field liver disease psoriasis history of qt >500msec history of torsades de pointes anemia from pyruvate kinase and g6pd deficiencies abnormal ekg with qt prolongation acquired or from birth history of jaundice or high fevers prior to developing covid-19 treatment with any of the medications listed in appendix ii treatment with any anti-epileptic medication treatment with any other drug not listed that affects the qt interval

refusal to sign informed consent form negative test for covid-19 by rt-pcr at screening severe disease symptomatically including pneumonia, respiratory distress, tachypnea, shortness of breath, temperature > 38 degrees; pleuritic pain, or frequent cough. known drug allergy to any of the investigational medications currently taking medication with known drug interactions with investigational medications (listed in appendix) prescription or other antiviral medications any comorbidities which constitute health risk for the subject pregnant or lactating females; weight < 110lb; porphyria established retinal disease inability to attend daily for 10 days any contraindications for treatment with hydroxychloroquine hypoglycemia known g6pd deficiency porphyria anemia neutropenia alcoholism myasthenia gravis skeletal muscle disorders maculopathy changes in visual field liver disease psoriasis history of qt >500msec history of torsades de pointes anemia from pyruvate kinase and g6pd deficiencies abnormal ekg with qt prolongation acquired or from birth history of jaundice or high fevers prior to developing covid-19 treatment with any of the medications listed in appendix ii treatment with any anti-epileptic medication treatment with any other drug not listed that affects the qt interval

1. refusal to sign informed consent form 2. negative test for covid-19 by rt-pcr at screening 3. severe disease symptomatically including pneumonia, respiratory distress, tachypnea, shortness of breath, temperature > 38 degrees; pleuritic pain, or frequent cough. 4. known drug allergy to any of the investigational medications 5. currently taking medication with known drug interactions with investigational medications (listed in appendix) 6. prescription or other antiviral medications 7. any comorbidities which constitute health risk for the subject 8. pregnant or lactating females; 9. weight < 110lb; 10. porphyria 11. established retinal disease 12. inability to attend daily for 10 days 13. any contraindications for treatment with hydroxychloroquine 1. hypoglycemia 2. known g6pd deficiency 3. porphyria 4. anemia 5. neutropenia 6. alcoholism 7. myasthenia gravis 8. skeletal muscle disorders 9. maculopathy 10. changes in visual field 11. liver disease 12. psoriasis 13. history of qt >500msec 14. history of torsades de pointes 14. anemia from pyruvate kinase and g6pd deficiencies 15. abnormal ekg with qt prolongation acquired or from birth 16. history of jaundice or high fevers prior to developing covid-19 17. treatment with any of the medications listed in appendix ii 18. treatment with any anti-epileptic medication 19. treatment with any other drug not listed that affects the qt interval

1. refusal to sign informed consent form 2. negative test for covid-19 by rt-pcr at screening 3. severe disease symptomatically including pneumonia, respiratory distress, tachypnea, shortness of breath, temperature > 38 degrees; pleuritic pain, or frequent cough. 4. known drug allergy to any of the investigational medications 5. currently taking medication with known drug interactions with investigational medications (listed in appendix) 6. prescription or other antiviral medications 7. any comorbidities which constitute health risk for the subject 8. pregnant or lactating females; 9. weight < 110lb; 10. porphyria 11. established retinal disease 12. inability to attend daily for 10 days 13. any contraindications for treatment with hydroxychloroquine 1. hypoglycemia 2. known g6pd deficiency 3. porphyria 4. anemia 5. neutropenia 6. alcoholism 7. myasthenia gravis 8. skeletal muscle disorders 9. maculopathy 10. changes in visual field 11. liver disease 12. psoriasis 13. history of qt >500msec 14. history of torsades de pointes 14. anemia from pyruvate kinase and g6pd deficiencies 15. abnormal ekg with qt prolongation acquired or from birth 16. history of jaundice or high fevers prior to developing covid-19 17. treatment with any of the medications listed in appendix ii 18. treatment with any anti-epileptic medication 19. treatment with any other drug not listed that affects the qt interval